Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension

Browse trials for

• Glaucoma 1,818
• Glaucoma, Open-Angle 929
• Ocular Hypertension 649
• Hypertension 6,689

Keywords

• open angle glaucoma
• Ocular Hypertension

Glaucoma

1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.

This study's planned enrollment of 70 is close to the median of 65 across 1,272 interventional studies indexed under Glaucoma.

Lead sponsor

This is the only study on the registry with JeniVision, Inc. as lead sponsor.

Study arms

• Experimental
  Randomized Part 2, Arm 1

  Dose 1 selected in Part I

  Drug: JV-GL1

• Experimental
  Randomized Part 2, Arm 2

  Dose 2 selected in Part I

  Drug: JV-GL1

• Active comparator
  Randomized Part 2, Arm 3

  Drug: Latanoprost 0.005% Ophthalmic Solution

Interventions

• DrugJV-GL1

  Experimental Treatment

• DrugLatanoprost 0.005% Ophthalmic Solution

  Active Control

Primary outcomes

1. Intraocular Pressure (IOP)

   Change from baseline in Intraocular Pressure (IOP)

   Time frame: From Baseline to Day 28 of Treatment